Filter
442
Text search:
mhGAP
Featured
Recommendations
98
New Publications
71
Language
Document type
No document type
250
Guidelines
69
Studies & Reports
40
Manuals
39
Training Material
14
Strategic & Response Plan
12
Situation Updates
7
Fact sheets
7
Resource Platforms
2
Brochures
1
Infographics
1
Countries / Regions
Syria
14
Ukraine
14
Latin America and the Carribbean
14
Russia
14
Global
14
Eastern Europe
12
Western and Central Europe
11
Nigeria
9
Sierra Leone
7
Kenya
6
Ethiopia
5
Uganda
5
India
5
Nepal
5
Ghana
4
South Sudan
4
South Africa
4
Mozambique
4
Brazil
4
Liberia
3
Iraq
3
Central African Republic
3
Peru
3
Angola
3
Middle East and North Africa
3
Congo, Democratic Republic of
2
Haiti
2
Lebanon
2
Turkey
2
China
2
Indonesia
2
Bangladesh
2
Sudan
2
Namibia
2
Colombia
2
Chile
2
Yemen
2
West and Central Africa
2
Asia
2
Africa
2
Jamaica
2
Portugal
2
Guinea
1
Morocco
1
Saudi Arabia
1
Zimbabwe
1
Pakistan
1
Jordan
1
Zambia
1
Cambodia
1
Malawi
1
Argentina
1
Burundi
1
Bolivia
1
Greece
1
Guatemala
1
Sri Lanka
1
South–East Asia Region
1
Eastern Europe and Central Asia
1
Italy
1
Albania
1
Laos
1
Iran
1
Georgia
1
Vietnam
1
Japan
1
Tunisia
1
Authors & Publishers
Publication Years
Category
Countries
95
Clinical Guidelines
27
Key Resources
17
Public Health
15
Women & Child Health
11
Capacity Building
7
Pharmacy & Technologies
2
Toolboxes
Mental Health
265
COVID-19
41
Conflict
25
HIV
14
Ebola & Marburg
12
Disability
9
Zika
9
Natural Hazards
6
Refugee
6
Caregiver
6
NCDs
5
TB
3
Health Financing Toolbox
3
Rapid Response
2
Global Health Education
2
Pharmacy
2
NTDs
2
Accessed: 10.03.2019
mhGAP Training Manual for the mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings – version 2.0 (for field test
...
WHO recommends interpersonal therapy (IPT) as a possible first line treatment for depression. With this new manual, the World Health Organization (WHO) gives guidance on the use of interpersonal therapy (IPT) using a 8 session group protocol. The manual - which is part of WHO’s
...
Данное руководство по применению групповой интерперсональной терапии (групповой ИПТ) в лечении депрессии дополняет собой mental health Gap Action Programme Intervention Guide (
...
utilisant le programme d'action de l'OMS «Combler les lacunes en santé mentale -Guide d'intervention humanitaire (mhGAP-GIH
Describir barreras y desafíos en la implementación del Programa de Acción Mundial para Reducir las Brechas de Atención en Salud Mental mhGAP, y determinar la asociación entre facilitadores de implementación, accesibilidad, aceptabilidad y supe
...
Este es un manual para capacitar a los agentes de salud de la comunidad sobre la manera de apoyar a las madres con depresión mediante técnicas cognitivo-conductuales basadas en datos científicos, que recomienda el programa mhGAP.
Objectives and scope of the document
This document was developed to provide recommended management strategies for problems and disorders that are specifically related to the occurrence of a major stressful event. The recommended strategies will form the basis of a new module to be added to the WHO
...
The Thinking Health manual outlines an evidence-based approach describing how community health workers can reduce prenatal depression through evidence-based cognitive-behavioural techniques recommended by the mhGAP programme.
This manual is the fi
...
Q7. SCOPING QUESTION: In adults with moderate-severe depressive disorder, what is the effectiveness and safety of antidepressant medication (ADM) in comparison with psychological treatment?
The WHO mhGAP programme’s existing guidelines recommen
...
BMC Medicine201210:107
https://doi.org/10.1186/1741-7015-10-107© Katchanov and Birbeck; licensee BioMed Central Ltd. 2012
Received: 10 July 2012Accepted: 24 September 2012Published: 24 September 2012
In 2011, the World Health Organization’s (WHO) mental health Gap Action Programme (
...
SUI supporting material
• Person stories
• Role plays
• Multiple choice questions
• Video link
Activity 2: mhGAP SUI module – assessment and management
The world is facing an unprecedented range of emergencies. In reaction to these complex adversities, many people experience considerable distress and impairment, and a minority may even go on to develop mental health conditions. Meanwhile, those with pre-existing mental health conditions may experie
...
Overview
Learning objectives
• Promote respect and dignity for people with psychoses.
• Name common presentations of psychoses.
• Name assessment principles of psychoses.
• Name management principles of psychoses.
• Perform an assessment for psychoses.
• Use effective communicatio
...
Q11. SCOPING QUESTIONS: In people with psychotic disorders (including schizophrenia and bipolar disorder) are recovery-oriented psychosocial strategies enhancing independent living and social skills (such as life skills and social skills training) feasible and effective?
Q12. SCOPING QUESTION: In people with psychotic disorders, including schizophrenia and bipolar disorder, are recovery-oriented strategies enhancing vocational and economic inclusion (such as supported employment) feasible and effective?
Group psychological help for adults impaired by distress in communities exposed to adversity
With this manual, the World Health Organization (WHO) is responding to requests from colleagues around the world for a group version of the manual Problem Management Plus (PM+), which was developed for adul
...
Overview
Learning objectives
• Name the general principles of essential care and practice.
• Name management principles of priority MNS conditions.
• Use effective communication skills in interactions with people with MNS conditions.
• Perform assessments for priority MNS conditions.
...
PSY supporting material
• Person stories
• Case scenarios
• Role plays
• Multiple choice questions
• Video links
SUI supporting material
• Person stories
• Role plays
• Multiple choice questions
• Video link
Q6: In individuals with psychotic disorders (including schizophrenia) who require long term antipsychotic treatment, are anticholinergic medications more effective in preventing or reducing extrapyramidal side-effects and/or improving treatment adherence than placebo/treatment as usual?
